Royalty Pharma plc (RPRX) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value (m); Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $16.32M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | (m) | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | $16.32M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $16.32M |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 10.03B USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | (m) | |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | 16.32M USD | Other Liabilities, Current |
| Reported other noncurrent obligations | 108.02M USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $16.32M
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Obligation categories | (m) |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $16.32M | (m) | $10.03B | (m) | (m) | (m) | $108.02M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $17.48M | (m) | $9.88B | (m) | (m) | (m) | $117.78M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $53.16M | (m) | $9.91B | (m) | (m) | (m) | $120.84M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $3.12M | (m) | $9.73B | (m) | (m) | (m) | $126.94M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $3.08M | (m) | $8.82B | (m) | (m) | (m) | $143.33M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $18.60M | (m) | $7.82B | (m) | (m) | (m) | $17.90M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $68.60M | (m) | $7.88B | (m) | (m) | (m) | $12.08M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $31.20M | (m) | $7.78B | (m) | (m) | (m) | $5.58M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $97.49M | (m) | $7.90B | (m) | (m) | (m) | $27.04M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $9.02M | (m) | $6.27B | (m) | (m) | (m) | $3.22M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $11.38M | (m) | $6.30B | (m) | (m) | (m) | $900.00K | (m) |
| 2023-09-30 | (m) | (m) | (m) | $0.00 | (m) | $6.27B | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | $0.00 | (m) | $7.31B | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | $0.00 | (m) | $7.25B | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $12.40M | (m) | $7.29B | (m) | (m) | (m) | $2.50M | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | $7.26B | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | $7.33B | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | $7.24B | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $0.00 | (m) | $7.27B | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | $0.00 | (m) | $7.35B | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | $4.31M | (m) | $6.11B | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $6.08B | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | $6.12B | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $6.19B | (m) | (m) | (m) | $110.00M | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $6.29B | (m) | (m) | (m) | $110.00M | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $6.31B | (m) | (m) | (m) | $0.00 | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |